A&R:造血PAD4在关节炎中的重要作用:胶原和粒细胞集落刺激因子诱导的C57BL/6小鼠关节炎模型

2022-07-13 MedSci原创 MedSci原创

该研究团队成功开发了一种适用于C57BL/6小鼠的关节炎模型。该模型具有与人类RA一致的一些特征,表明造血PAD4是关节炎发展的重要贡献者。

目的全基因组关联研究已将编码肽基精氨酸脱氨酶4 (PAD4)PADI4与类风湿性关节炎(RA)联系起来。PAD4促进中性粒细胞胞外陷阱(NET)的形成。本研究旨在调查PAD4的起源和NET形成在C57BL/6小鼠关节炎模型中的重要性。

方法为了在胶原诱导的关节炎(CIA)模型中有效使用C57BL/6小鼠,研究人员在第21天引入了连续4天的粒细胞集落刺激因子(G-CSF)与免疫增强剂。在模型中评估了整体Padi4缺陷(Padi4-/-)的小鼠和具有造血谱系特异性Padi4缺陷(Padi4Vav1Cre/+)的小鼠。

结果G-CSF显著增加了CIA的发病率和严重程度。G-CSF处理的小鼠血浆中的瓜氨酸组蛋白H3 (Cit-H3)水平升高,而溶剂处理的小鼠则未见此现象。免疫荧光显微镜显示Cit-H3 G-CSF处理的小鼠的滑膜组织中沉积。在G-CSF改进的CIA模型中,Padi4+/+小鼠相比,Padi4-/-小鼠出现较轻的关节炎,血清白细胞介素6和血浆Cit-H3水平较低,滑膜组织中Cit-H4水平较低,微计算机断层扫描显示的骨侵蚀较少。同样,Padi4fl/fl小鼠相比,Padi4Vav1Cre/+ 小鼠出现较轻的关节炎,并呈现与Padi4/小鼠相同的表型。

结论该研究团队成功开发了一种适用于C57BL/6小鼠的关节炎模型,该模型完全符合动物福利的高标准。观察到雄性小鼠的关节炎发病率> 90%和可检测到的NET标志物。该模型具有与人类RA一致的一些特征,表明造血PAD4在关节炎发展中的重要作用,并且可能在未来的 RA 研究中证明是有用的。

出处:Fukui, S., Gutch, S., Fukui, S., Cherpokova, D., Aymonnier, K., Sheehy, C.E., Chu, L. and Wagner, D.D. (2022), The Prominent Role of Hematopoietic Peptidyl Arginine Deiminase 4 in Arthritis: Collagen- and Granulocyte Colony-Stimulating Factor–Induced Arthritis Model in C57BL/6 Mice. Arthritis Rheumatol, 74: 1139-1146. https://doi.org/10.1002/art.42093

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023571, encodeId=d54120235e13c, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 09 20:52:28 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232705, encodeId=cce51232e0518, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e7e82338464, createdName=12286003m71暂无昵称, createdTime=Fri Jul 15 22:48:32 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232355, encodeId=46e71232355e1, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Jul 14 07:30:22 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266490, encodeId=466e12664908c, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494807, encodeId=46bf149480e59, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023571, encodeId=d54120235e13c, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 09 20:52:28 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232705, encodeId=cce51232e0518, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e7e82338464, createdName=12286003m71暂无昵称, createdTime=Fri Jul 15 22:48:32 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232355, encodeId=46e71232355e1, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Jul 14 07:30:22 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266490, encodeId=466e12664908c, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494807, encodeId=46bf149480e59, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
    2022-07-15 12286003m71暂无昵称

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2023571, encodeId=d54120235e13c, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 09 20:52:28 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232705, encodeId=cce51232e0518, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e7e82338464, createdName=12286003m71暂无昵称, createdTime=Fri Jul 15 22:48:32 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232355, encodeId=46e71232355e1, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Jul 14 07:30:22 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266490, encodeId=466e12664908c, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494807, encodeId=46bf149480e59, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
    2022-07-14 xulv123

    认真学习~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2023571, encodeId=d54120235e13c, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 09 20:52:28 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232705, encodeId=cce51232e0518, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e7e82338464, createdName=12286003m71暂无昵称, createdTime=Fri Jul 15 22:48:32 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232355, encodeId=46e71232355e1, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Jul 14 07:30:22 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266490, encodeId=466e12664908c, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494807, encodeId=46bf149480e59, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
    2022-07-14 lmm397
  5. [GetPortalCommentsPageByObjectIdResponse(id=2023571, encodeId=d54120235e13c, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 09 20:52:28 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232705, encodeId=cce51232e0518, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e7e82338464, createdName=12286003m71暂无昵称, createdTime=Fri Jul 15 22:48:32 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232355, encodeId=46e71232355e1, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Jul 14 07:30:22 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266490, encodeId=466e12664908c, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494807, encodeId=46bf149480e59, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Jul 14 01:52:28 CST 2022, time=2022-07-14, status=1, ipAttribution=)]
    2022-07-14 俅侠

相关资讯

A&R:Semaphorin 3B在血清诱导的关节炎模型中的中心作用和在类风湿关节炎患者的水平降低

信号素3B (Sema3B)表达在关节炎小鼠模型中起保护作用。在RA患者中,血清中Sema3B的表达水平取决于疾病阶段,表明在疾病发作和进展中具有不同的调节作用。

A&R:类风湿因子和抗修饰蛋白抗体反应性汇聚在IgG表位上

抗修饰蛋白抗体(AMPA)结合的表位库包括修饰的IgG表位,IgG被定位为连接RF和AMPA的不同反应性的共同抗原。

Rheumatology:类风湿性关节炎和原发性干燥综合征的亚临床动脉粥样硬化特征——BAFF基因变异的影响

比较类风湿性关节炎(RA)和原发性干燥综合征(SS)两个临床实体之间的亚临床动脉粥样硬化情况,并确定BAFF基因变异是否会改变动脉粥样硬化风险。

ARD:RA患者初始治疗使用糖皮质激素后停药成功率如何?

在类风湿性关节炎(RA)患者临床试验中,糖皮质激素(GC)停药大多是成功的,尽管 22%的开始GC桥接治疗的患者在12个月时仍然或再次使用GC,在24个月时为10%。

ARD:托法替布与心血管结局风险:托法替布在类风湿关节炎常规护理患者中的安全性(STAR-RA)研究结果

该研究没有发现托法替尼在现实世界中治疗的类风湿性关节炎(RA)患者心血管结局风险增加的证据;然而,在有心血管危险因素的RA患者中,托法替尼与心血管结局风险增加相关,尽管在统计学上不显著。

ARD:65 岁以上类风湿关节炎患者的低剂量激素长期收益良好

附加的低剂量泼尼松龙对已确诊类风湿性关节炎(RA)的老年患者具有长期有益的影响,在大多数非严重不良事件(AE)患者中的益处增加。